A Cross-Sectional Study on Board Certified Pharmacists in Arab Countries 2018 Update

Authors: Mohamed Anwar Hammad, Khaled Mohamed Al Akhali, Yasmin Elsobky

Abstract:

Board certification is a voluntary process that confirms a pharmacist's capability, competency, education, skills, and proficiency beyond what is essential for licensure. This analysis was intended to investigate the prevalence of board-certified pharmacists in the Arab countries and compare the Board of Pharmacy Specialties (BPS) between Egypt, Saudi Arabia, and Canada. A cross-sectional study was conducted. The data were mined from the BPS website. Data were managed by IBM SPSS Statistics 23.0 and presented as descriptive statistics. Of 36918 Board certified pharmacists (BCPs) until February 2018, only 4038 (10.9%) were from the outside United States of America. From 4038 BCPs, about 1782 (44.1%) were from Arab nations. Egypt has the top prevalence of the BPS among the Arab countries 937 (52.6%) BCPs. However, the Kingdom of Saudi Arabia comes in the second position 442 (24.8%). Pharmacotherapy (BCPS), nutrition support pharmacy (BCNSP), critical care pharmacy (BCCCP) and oncology pharmacy (BCOP) are the highest specialties by 1474 (82.7%), 114 (6.4%), 61 (3.42%) and 60 (3.37%) respectively, while, infectious diseases pharmacy (AQID), cardiology pharmacy (AQCD) and nuclear pharmacy (BCNP) are the lowest prevalence of specialties by 7 (0.4%), 6 (0.3%) and 1 (0.06%) respectively. Added qualifications were canceled and became a new specialty in BPS as the rest of the specialties. Both infectious diseases and cardiology specialties exams are not conducted yet all over the world from the beginning of 2018. Egypt has the second prevalence 937 (2.54%), before Canada 920 (2.49%) and after United States of America 32880 (89.06%) in the worldwide in terms of BCPs. In conclusion the BCPS is the uppermost specialty; however, there is still a need for all the other specialties. In a short period, BCCCP jumped to the third position. Cardiology and infectious disease will be new specialties. Egyptian pharmacists are in the top of Arab countries, and 2nd in worldwide BCPs.

Keywords: AQCD, AQID, Arab Countries, BCACP, BCCCP, BCGP, BCNP, BCNSP, BCOP, BCPPS, BCPS, BCPP, Board of Pharmacy Specialties, BPS, Canada, Egypt, Saudi Arabia, USA.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.3669142

References:

[1] Board of Pharmacy Specialties. About BPS Board of Pharmacy Specialties. Available from: https://www.bpsweb.org/bps-specialties/. (Accessed on 29- Jan- 2018).
[2] About BPS - Board of Pharmacy Specialties". www.bpsweb.org. Retrieved 24 January 2018.
[3] D. Witt. BPS Board Certification in the Real World. Available from: https://www.bpsweb.org/impact-of-bps-certification/bps-board-certification-in-the-real-world/ (Accessed: 29- Jan- 2018).
[4] M. A. Hammad, Khaled M. AL-Akhali, Asif S. Mohammad, Rahaf M. Alqahtani, Sahar H. Alshhrany, Nada M. Alhassan, Fatma R. Abo Essa. Prospective Study on Adherence and Pharmacoeconomics of Antibiotic Switching from Intravenous to Oral Route. Journal of Pharmaceutical Research & Clinical Practice, Oct-Dec 2015;5(4): 7-13.
[5] J.J. Saseen, S. E. Grady, L. B. Hansen, B. M. Hodges, S. J. Kovacs, L. D. Martinez, J. E. Murphy, et al. Future Clinical Pharmacy Practitioners Should Be Board-Certified Specialists. Pharmacotherapy, 2006;26(12): 1816-1825.
[6] Board of Pharmacy Specialities. Making a Difference. Available from: https://www.bpsweb.org/impact-of-bps-certification/making-a-difference/. (Accessed on: 29- Jan- 2018).
[7] K. Erickson. BPS certification: Keeping the profession moving forward. Pharmacy Today. JULY 2013;19(7): 8.
[8] Board of Pharmacy Specialties. Find A Board Certified Pharmacist. Available from: https://portalbps.cyzap.net/dzapps/dbzap.bin/apps/assess/webmembers/managetool?webid=BPS&pToolCode=certrecord&pRecCmd=StatsByLocation&pPrint=Yes. (Accessed on: 31- Jan- 2018).
[9] M. A. Hammad, M. A. Al-Mansoub, M. Qamar. Board Certified Pharmacists in Arab Countries: Data Analysis and Current Needs. AMPSR, 2017;1(2): 36-38.
[10] M. H. Elnaem, S. Q. Jamshed, R. M. Elkalmi. Board specialty certifications for pharmacists in Arab Countries: Current needs and recommendations. Arch Pharma Pract, 2017;8(1): 1-2. DOI:10.4103/2045-080X.199618.
[11] N. M. El Agroudy, F. A. Shafiq, S. Mokhtar. The Effect of the Rise in the Dollar Rate on the Egyptian Economy. Middle East J. Appl. Sci. 2015;5(2): 509-514.
[12] Z. Alkhalisi. Why Egypt just let its currency crash by 48%. CNN Money. 2016 available from: http://money.cnn.com/2016/11/03/news/economy/egypt-pound-devaluation-bailout/index.html. (Accessed on: 30- Jan- 2018).
[13] The World Bank. Economic Effects of War and Peace in the Middle East and North Africa. Available from: http://www.worldbank.org/en/news/press-release/2016/02/03/economic-effects-of-war-and-peace-in-the-middle-east-and-north-africa.
[14] P. Justino. How Does Violent Conflict Impact on Individual Educational Outcomes? The Evidence So Far. 2011/ED/EFA/MRT/PI/30.
[15] United Nations Educational, Scientific and Cultural Organization (UNESCO). The hidden crisis: Armed conflict and education. Paris, France 2011.
[16] Y. El-Sobky, D. A. Atta, A. Derzawy, M. A. Hammad. The Impact of the American Board Certification on the Egyptian Pharmacists. Arch Med Pharm Sci Res, 2017;1(1): 02-10.
[17] S. Suzuki, H. Sakurai, K. Kawasumi, M. Tahara, S. Saito, K. Endo. The impact of pharmacist certification on the quality of chemotherapy in Japan. Int J Clin Pharm, 2016;38: 1326. PMID: 27573721. DOI: 10.1007/s11096-016-0374-6.
[18] L. K. Sharp, P. G. Bashook, M. S. Lipsky, S. D. Horowitz, S.H. Miller. Specialty board certification and clinical outcomes: the missing link. Acad Med, 2002;77(6): 534–42. PMID: 12063199.
[19] J. P. Engle, B. L. Erstad, D. C. Anderson, M. H. Bucklin, A. Chan, A. R. Donaldson, et al. Minimum Qualifications for Clinical Pharmacy Practice Faculty. American College of Clinical Pharmacy. Pharmacotherapy 2014;34(5): e38–e44. DOI: 10.1002/phar.1422.
[20] E. N. Grosch. Does specialty board certification influence clinical outcomes? J Eval Clin Pract, 2006;12(5): 473–81. PMID: 16987109 DOI: 10.1111/j.1365-2753.2006.00556.x.
[21] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, A. Kharshid, N. A. Aziz, T. M. Elsayed. A Prospective Study on the Evaluation of Statins Usage on HbA1c Control among Type 2 Diabetes Mellitus in an Outpatients Setting. World Academy of Science, Engineering and Technology International Journal of Pharmacological and Pharmaceutical Sciences 2017;4(8): 805. DOI10.13140/RG.2.2.27914.36806.
[22] M. A. Hammad, A. A. Khamis, K. M. Al- Akhali, T. M. Elsayed, A. M. Alasmri, E. M. Al-Ahmari, E. M. Mossa, N. M. Al-Gahtani, Y. El-Sobky. Evaluation of Drug Dosing in Renal Failure. IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS). 2016;11(5)3: 39-50. DOI: 10.9790/3008-1105033950.
[23] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, A. Sha'aban. The equivalence between the Malay and UK English versions of mini-Addenbrooke's cognitive examination. Malaysian Journal of Pharmacy. 2017;3(1): 28.
[24] K. Hazama. "Pharmacy 3.0" and the meaning of vital signs for pharmacists. Yakugaku Zasshi. 2012;132(1): 17-20. PMID: 22214574.
[25] M. A. Hammad, K. M. Alakhali, M. Hattan, D. A. Mohamed Noor, S. A. Syed Sulaiman, A. M. Kharshid, A. A. Khamis. Asthma in Saudi Arabia: Risk Factors and Pharmacotherapy. Indo American Journal of Pharmaceutical Research, 2016;6(11): 6814-6821. DOI10.1044/1980-iajpr.161043.
[26] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, N. A. Aziz, Y. Elsobky. A prospective study of prevalence of uncontrolled glycaemia in Type 2 diabetes mellitus outpatients. Pharmacotherapy 2016;36(7): e83–e138. DOI: 10.13140/RG.2.1.4848.0247/1.
[27] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, M. A. Al-Mansoub, M. Qamar. A Retrospective Study on the Age of Onset for Type 2 Diabetes Diagnosis. World Academy of Science, Engineering and Technology International Journal of Pharmacological and Pharmaceutical Sciences 2017;4(8): 807. DOI: 10.13140/RG.2.2.24224.69124.
[28] J. Beck, D. A. Greenwood, L. Blanton, S. T. Bollinger, M. K. Butcher, J. E. Condon, et al. 2017 National Standards for Diabetes Self-Management Education and Support. The Diabetes Educator 2017;43(5): 449–464. https://doi.org/10.1177/0145721717722968.
[29] K. M. Alakhali, A. Ansari, M. A. Hammad, Analysis of Prevalence, Risk Factor and Pharmacotherapy of Hypertension in Outpatients. The 10th Annual Scientific Research Day for Medical, Applied and Basic Sciences, King Khalid University, May 5, 2014: P68. DOI: 10.13140/RG.2.1.3687.5288.
[30] M. A. Alakhali, M. A. Ansari, M. A. Hammad. Analysis of Prevalence, Risk Factor and Pharmacotherapy of Hypertension in Outpatients. Indian Journal of Pharmacy Practice. Oct-Dec, 2013;(6)4: 64-66.
[31] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, A. A. Khamis, A. Kharshid, N. A. Aziz Comparison of Statins Dose Intensity on HbA1c Control in Outpatients with type 2 Diabetes: A Prospective Cohort Study. ICDDCPT 2017: 19th International Conference on Drug Development, Clinical Pharmacy and Therapeutics. International Journal of Pharmacological and Pharmaceutical Sciences 2017;4(8): 806. DOI: 10.13140/RG.2.2.19669.93922.
[32] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, A. A. Khamis, A. Kharshid, N. A. Aziz. Comparison of Statins Dose Intensity on HbA1c Control in Outpatients with Type 2 Diabetes: A Prospective Cohort Study. World Academy of Science, Engineering and Technology International Journal of Medical, Health, Biomedical, Bioengineering and Pharmaceutical Engineering 2017;11(8): 423-428. scholar.waset.org/1999.9/10007661.
[33] MA Hammad, Sulaiman SA, Aziz NA, Noor DA. Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice. J Res Med Sci 2018;23:XX-XX. DOI: 10.4103/jrms.JRMS_100_18
[34] S. A. Syed Sulaiman, D. A. Mohamed Noor, M. A. Hammad, K. M. AlAkhali, A. M. Alasmri, E. M. Al-Ahmari, E. M. Mossa, N. M. AlGahtani. Prospective study of evaluation of antibiotics dosage adjustment in patients with chronic renal failure at Aseer hospital. JAASP 2015;1: 142.
[35] M. A. Hammad et al., Prospective Study of Evaluation of Drug Dosage Adjustment in Patient with Chronic Renal Failure at Aseer Hospital. The 10th Annual Scientific Research Day for Medical, Applied and Basic Sciences, King Khalid University, 5.05.2014: P92. DOI: 10.13140/RG.2.1.1918.0567.
[36] K. Al Akhali, M. A. Hammad, M. A. Ansari. Evaluation of Prevalence and Pattern of Anemia – A Hospital Based Study in Aseer Province, Kingdom of Saudi Arabia. Journal of Experimental Medical & Surgical Research. 2013;2: 32 -35.
[37] M. Luisetto, B. Nili-Ahmadabadi, G. R. Mashori. The Clinical Pharmacists Main Focus. J Appl Pharm 2017;9: 4. DOI: 10.21065/1920-4159.1000e114.
[38] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, Tarek Mohamed Elsayed. Statins Effects on Diabetic Retinopathy Among Patients with Type 2 Diabetes Mellitus. International Journal of Ophthalmology & Visual Science. 2017;2(4): 106-114. DOI: 10.11648/j.ijovs.20170204.15.
[39] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman, A. Sha'aban, N. A. Aziz. Statins Effects on Cataract Among Patients with Type 2 Diabetes Mellitus. Malaysian Journal of Pharmacy. 2017;3(1): 28.
[40] S. M. Carolyn. Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting. Dovepress. 2014;3: 11-24. DOI: https://doi.org/10.2147/IPRP.S40428.
[41] K. M. Alakhali, M. Selim, M. A. Hammad. Evaluation of therapeutic drug monitoring of cyclosporine and tacrolimus in kidney transplant patients. JPCS Jan-March 2014;8: 18-25. Available from: https://www.researchgate.net/publication/270337774_Evaluation_of_therapeutic_drug_monitoring_of_cyclosporine_and_tacrolimus_in_kidney_transplant_patients.
[42] M. A. Hammad, K. M. AL-Akhali, A. T. Mohammed. Evaluation of surgical antibiotic prophylaxis in Aseer area hospitals in Kingdom of Saudi Arabia. JPCS Jan-March 2013;6: 1-7. Available from: https://www.researchgate.net/publication/268777168_Evaluation_of_surgical_antibiotic_prophylaxis_in_Aseer_area_hospitals_in_Kingdom_of_Saudi_Arabia.
[43] M. Luisetto. Infectious Disease Pharmaceutical Care: The Role of the Clinical Pharmacists to Improve Clinical Outcomes 2017. J Antimicrob Agents 2017;3: 143. DOI:10.4172/2472-1212.1000143.
[44] M. Qamar, M. A. Hammad, F. A. Shaikh, S. Ahmad. Knowledge and Attitude Towards Antibiotic Usage Among General Public in Kuala Lumpur, Malaysia. Malaysian Journal of Pharmacy. 2017;3(1): 38. Available from: https://www.researchgate.net/publication/321097366_knowledge_and_attitude_towards_antibiotic_usage_among_general_public_in_kuala_lumpur_malaysia.
[45] E. B. McNeely. Treatment Considerations and the Role of the Clinical Pharmacist Throughout Transitions of Care for Patients with Acute Heart Failure. Journal of Pharmacy Practice. 2017;30(4): 441-450. PMCID: PMC5524196 DOI: 10.1177/0897190016645435.
[46] T. J. Schindel, N. Yuksel, R. Breault, J. Daniels, S. Varnhagen, C. A. Hughes. Perceptions of pharmacists' roles in the era of expanding scopes of practice. Research in Social and Administrative Pharmacy 2017;13(1): 148–161. DOI: http://sci-hub.tw/10.1016/j.sapharm.2016.02.007.
[47] M. A. Hammad, S. Azhar Syed Sulaiman, A. Aly, D. A. Mohamed Noor. Malaysian Adaptation of the Mini-Addenbrooke’s Cognitive Examination (M-ACE). World Applied Sciences Journal 2017;35(11): 2315-2320. DOI: 10.5829/idosi.wasj.2017.2315.2320.
[48] M. A. Hammad, D. A. Mohamed Noor, S. A. Syed Sulaiman. The effect of patients' adherence on HbA1c control. AMPSR, 2017;1(1): 30-35. Available from: https://www.researchgate.net/publication/318909992_the_effect_of_patient%27s_adherence_on_hba1c_control.
[49] J. J. Saseen, T. L. Ripley, D. Bondi, J. M. Burke, L. J. Cohen, S. McBane, et al. ACCP Clinical Pharmacist Competencies. Pharmacotherapy 2017;37(5): 630-636. PMID: 28464300 DOI: 10.1002/phar.1923.
[50] M. A. Hammad, B. Tangiisuran, A. M. Kharshid, N. Abdul-Aziz, Y. Hassan, N. A. Aziz, et al. Drug‑drug interaction‑related uncontrolled glycemia. J Pharm Bioall Sci 2017;9: 221-8. DOI: 10.4103/JPBS.JPBS_26_17.
[51] M. A. Hammad, B. Tangiisuran, N. Abd El Aziz, Y. Hassan. A prospective study of uncontrolled glycaemia secondary to drug- drug interactions in type 2 diabetes mellitus patients at Penang general hospital in Malaysia. Pharmacotherapy 2013;33(5): e50. DOI: 10.1002/phar.1300.
[52] N. Horikawa, N. Kuroki, T. Hosaka, S. Nomura, H. Nishimura, K. Yamashita, et al. Introduction of a board certification system for the Japanese Society of General Hospital Psychiatry. Seishin Shinkeigaku Zasshi, 2003;105(3): 320-3. PMID: 12728518.
[53] F. G. Pradel, F. B. Palumbo, L. Flowers, C. D. Mullins, S. T. Haines, D. S. Roffman. White paper: value of specialty certification in pharmacy. J Am Pharm Assoc, 2004’44(5): 612–20.
[54] B. Lofgren. Should Pharmacists Become Board Certified? Pharmacy Time. January 13, 2015. Available from: http://www.pharmacytimes.com/contributor/beth-lofgren-pharmd-bcps/2015/01/should-pharmacists-become-board-certified. (Accessed on: 29-Jan- 2018).
[55] C. A. Pedersen, P. J. Schneider, D. J. Scheckelhoff. ASHP national survey of pharmacy practice in hospital settings: Prescribing and transcribing—2016. American Journal of Health-System Pharmacy September 2017;74(17): 1336-1352; DOI: http://sci-hub.tw/10.2146/ajhp170228.
[56] M. Y. L. Siaw, Y. Ko, D. C. Malone, K. Y. K. Tsou, Y. J. Lew, D. Foo, et al. Impact of pharmacist- involved collaborative care on the clinical, humanistic and cost outcomes of high- risk patients with type 2diabetes (IMPACT): a randomized controlled trial. J Clin Pharm Ther. 2017;42: 475–482. https://doi.org/10.1111/jcpt.12536.
[57] A. Sha,aban, A. Jatau, A. Aly, M. A. Hammad, E. A. Casmir, O. O. Olubukola. Drug utilisation pattern and associated adverse drug events in hypertensive patients at a tertiary healthcare facility in south-west Nigeria. Malaysian Journal of Pharmacy. 2017;3(1): 55. Available from: https://www.researchgate.net/publication/320919252_drug_utilisation_pattern_and_associated_adverse_drug_events_in_hypertensive_patients_at_a_tertiary_healthcare_facility_in_south-west_nigeria.
[58] M. A. Chisholm-Burns, J. K. Lee, C. A. Spivey, M. Slack, R. N. Herrier, E. Hall-Lipsy, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010 Oct;48(10): 923-33. DOI: 10.1097/MLR.0b013e3181e57962.
[59] A. Aly, Z. Yusoff, S. Othman, S. A. Syed Sulaiman, A. Kharshid, M. A. Hammad, A. Sha’aban. Patient safety knowledge, attitudes, and skills of undergraduate pharmacy students at University of Science, Malaysia. PHARMACOTHERAPY. 2017;37(6): e44. DOI: 10.1002/phar.1815.
[60] B. Shay, L. Louden, B. Kirschenbaum. Specialty Pharmacy Services: Preparing for a New Era in Health-System Pharmacy. Hospital Pharmacy. 2015;50(9): 834-839. DOI: 10.1310/hpj5009-834.
[61] M. H. Rim, L. Smith, M. Kelly. Implementation of a patient-focused specialty pharmacy program in an academic healthcare system. American Journal of Health-System Pharmacy June 2016;73(11): 831-838; DOI: http://sci-hub.tw/10.2146/ajhp150947.
[62] Carver, J. B. Lee, B. Newman. Advancing Patient Care Through Specialty Pharmacy Services in an Academic Health System. J Manag Care Spec Pharm, Aug 2017;23(8): 815-820. https://doi.org/10.18553/jmcp.2017.23.8.815.
[63] N. A. Ahmad, N. H. Abd-Jabar, N. H. Awaluddin, N. Kamaruddin, N. Mohd-Rasid, T. M. Elsayed, et al. How community pharmacists perceive generic substitution impact on community pharmacies profits in absence of medicines price control policy: A Malaysian pilot nationwide study. Journal of Generic Medicines. 2017;13(2): 64–72. DOI: 10.1177/1741134316680390.
[64] K. A. Mullican, S. J. Francart. The role of specialty pharmacy drugs in the management of inflammatory diseases. American Journal of Health-System Pharmacy June 2016;73(11): 821-830; DOI: http://sci-hub.tw/10.2146/ajhp150727.
[65] J. Jacobi, S. Ray, I. Danelich, E. D. Ashley, S. Eckel, R. Guharoy, et al. Impact of the Pharmacy Practice Model Initiative on Clinical Pharmacy Specialist Practice. Pharmacotherapy 2016;36(5): e40–e49. DOI: 10.1002/phar.1745.
[66] B. L. Carter. Evolution of Clinical Pharmacy in the US and Future Directions for Patient Care. Drugs & aging. 2016;33(3): 169-177. doi:10.1007/s40266-016-0349-2.
[67] Washington, D.C. BPS To Introduce Practice Eligibility Attestation Requirement in 2019. Retrieved on 11 November 2018 from https://www.bpsweb.org/2018/05/29/bps-to-introduce-practice-eligibility-attestation-requirement-in-2019/
[68] Board of Pharmacy Specialties (BPS). Added Qualifications. Retrieved on 11 November 2018 from https://www.bpsweb.org/bps-specialties/added-qualifications/
[69] Board of Pharmacy Specialties (BPS). Board of Pharmacy Specialties Seeks Pharmacists to serve on its Compounded Sterile Preparations Pharmacy Specialty Council. Mar 6, 2018. Available from: https://www.bpsweb.org/2018/02/27/new-specialty-compounded-sterile-preparations/.
[70] S. Anders, V. Basalyga, M. Campara, A. Condon, N. A. Pilch, J. B. Skelton, C. E. Webb. A Petition to the Board of Pharmacy Specialties Requesting Recognition of Solid Organ Transplantation Pharmacy Practice as a Specialty. March 2018. Available from: https://www.bpsweb.org/wp-content/uploads/BPSSOTPetition032818.pdf.